Medpace Holdings (MEDP) EBITDA (2015 - 2026)

Medpace Holdings has reported EBITDA for 12 years, with the latest figure at $148.3 million in Q1 2026.

• For the quarter ending Q1 2026, EBITDA rose 23.32% year-over-year to $148.3 million; the trailing twelve-month figure through Mar 2026 stood at $590.2 million (up 21.89% YoY), and the FY2025 full-year result was $562.1 million, up 18.43% from the prior year.
• EBITDA for Q1 2026 stood at $148.3 million, down from $160.2 million in the prior quarter.
• The five-year high for EBITDA was $160.2 million in Q4 2025, with the low at $64.9 million in Q2 2022.
• Historically, EBITDA has averaged $108.5 million across 5 years, with a median of $110.7 million in 2024.
• Annual changes were most pronounced in 2022 — EBITDA soared 43.29% — and 2025, when it rose 8.6%.
• Medpace Holdings' EBITDA stood at $81.5 million in 2022, then rose by 15.03% to $93.7 million in 2023, then jumped by 41.36% to $132.5 million in 2024, then rose by 20.88% to $160.2 million in 2025, then decreased by 7.45% to $148.3 million in 2026.
• The last three EBITDA figures came in at $148.3 million (Q1 2026), $160.2 million (Q4 2025), and $148.6 million (Q3 2025), per Business Quant data.